Danaher Co. (NYSE:DHR) Shares Acquired by Regal Investment Advisors LLC

Regal Investment Advisors LLC grew its holdings in Danaher Co. (NYSE:DHR) by 1.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,581 shares of the conglomerate’s stock after buying an additional 157 shares during the period. Regal Investment Advisors LLC’s holdings in Danaher were worth $2,144,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Tsfg LLC raised its position in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher in the second quarter valued at about $25,000. nVerses Capital LLC purchased a new stake in shares of Danaher in the second quarter valued at about $25,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Danaher in the first quarter valued at about $30,000. Finally, Richardson Financial Services Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at about $42,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 0.9 %

Shares of DHR opened at $278.02 on Tuesday. The stock has a market capitalization of $205.93 billion, a PE ratio of 47.12, a P/E/G ratio of 4.55 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company’s 50-day simple moving average is $270.77 and its 200-day simple moving average is $258.06.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.05 earnings per share. Analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 over the last 90 days. 11.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Robert W. Baird upped their price objective on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Evercore ISI dropped their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Wells Fargo & Company assumed coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 target price on shares of Danaher in a research note on Friday, September 6th. Finally, Bank of America increased their target price on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.